People who are genetically predisposed to myasthenia gravis (MG) are more likely to develop Graves’ disease and Hashimoto’s thyroiditis, two autoimmune diseases of the thyroid gland, according to a study in China. Researchers also found a genetic link in the opposite direction, where being genetically predisposed to Graves’ disease…
News
Being younger, having more symptom-free periods, and a delayed positive antibody test were identified as risk factors for a delayed diagnosis of myasthenia gravis (MG) in a study conducted in Denmark. While the study’s findings noted a trend toward shorter diagnosis times in more recent years, the researchers noted…
Treatment with ARGX-119, an experimental therapy being developed by Argenx, led to improvements in muscle strength and survival in a mouse model of myasthenia gravis (MG) driven by self-reactive antibodies that target the muscle-specific kinase (MuSK) protein, a study shows. While the findings indicated ARGX-119 may ease…
People with myasthenia gravis (MG) are just as likely to have upper respiratory tract infections (URTIs) as people in the general population, a study in Saudi Arabia suggests. Certain treatments used to manage MG, such as rituximab, an antibody-based therapy sometimes used off-label for that purpose, might increase…
The U.S. Food and Drug Administration (FDA) has granted priority review to Johnson & Johnson’s request to approve nipocalimab for patients with generalized myasthenia gravis (gMG) who are positive for the most common types of MG-causing self-reactive antibodies. …
Cyrus Biotechnology has selected CYR212 as its clinical development candidate for myasthenia gravis (MG) and other autoimmune diseases driven by immunoglobulin G (IgG) self-reactive antibodies, the company announced in a press release. According to the U.S.-based biotech, CYR212’s profile — as seen in preclinical data culled from…
Nearly all adults who underwent a stem cell transplant for treatment-resistant myasthenia gravis (MG) achieved remission or had minimal symptoms that did not require further treatment, according to a small study. “Studies investigating the efficacy and safety of [stem cell transplant] in the treatment of refractory [or treatment-resistant] MG…
Soleo Health, a specialty pharmacy company, has opened a new ambulatory infusion site in the Denver area for people with myasthenia gravis (MG) and other diseases requiring infusion therapies. The Greenwood Village, Colorado, location offers private infusion sites…
The incidence of myasthenia gravis (MG) is increasing in the Czech Republic, with about 40% of the patients being in their economically productive age, between 15 and 65. That’s according to data from a Czech patient registry that also found about a third of these patients couldn’t work at…
Throughout 2024, the team at Myasthenia Gravis News has brought you the latest updates on research advances and treatment options for myasthenia gravis (MG). We look forward to continuing to serve the MG community in the years to come. Here, we’ve compiled a list of the 10 most-read articles…
Recent Posts
- Women with MG have higher risk of complications during pregnancy
- This year, I’m pushing boundaries in how I live with MG
- Early rituximab treatment may improve long-term outcomes in gMG
- Vyvgart plus low-dose steroids is safer treatment for severe gMG: Study
- Guest Voice: Don’t let fear hold you back from living fully with MG